A carregar...
ACTR-21. UPDATED RESULTS OF A PHASE I DOSE-ESCALATION, DOSE-EXPANSION STUDY OF DISULFIRAM AND ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
BACKGROUND: Disulfiram has promising preclinical activity against glioblastoma (GBM) as well as synergy with temozolomide. In a phase I study for newly diagnosed GBM after chemoradiotherapy, we have previously shown the maximum tolerated dose (MTD) of disulfiram with adjuvant temozolomide is 500mg p...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692522/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.016 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
A carregar...